Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK–positive anaplastic large-cell lymphoma-Reference-Cited by-同舟云学术

Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK–positive anaplastic large-cell lymphoma

Published:2014-01-16 Issue:3 Volume:123 Page:334-337
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Damm-Welk Christine¹,Mussolin Lara²³,Zimmermann Martin¹,Pillon Marta²,Klapper Wolfram⁴,Oschlies Ilske⁴,d’Amore Emanuele S. G.⁵,Reiter Alfred¹,Woessmann Wilhelm¹,Rosolen Angelo²

Affiliation:

1. Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster Study Center, Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen, Germany;

2. Department of Pediatric Hematology and Oncology, University of Padova, and

3. Istituto di Ricerca Pediatrico Fondazione Città della Speranza, Padova, Italy;

4. Institute of Pathology, Hematopathology Section and Lymph Node Registry, Christian-Albrechts University, Kiel, Germany; and

5. Pathology Unit, Ospedale San Bortolo, Vicenza, Italy

Abstract

Key Points Early MRD positivity in NPM-ALK–positive ALCL correlates with a very high relapse risk and inferior survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/3/334/1377616/334.pdf

Reference22 articles.

1. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.;Brugières;J Clin Oncol,2009

2. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children’s Cancer Group Study 5941.;Lowe;Pediatr Blood Cancer,2009

3. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol.;Rosolen;Cancer,2005

4. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.;Seidemann;Blood,2001

5. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation.;Damm-Welk;Br J Haematol,2009

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12

2. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

3. Minimal Disseminated Disease Continues to Impact Outcomes Even in the Era of Targeted Therapy in Childhood ALK+ Anaplastic Large Cell Lymphoma, What More Do We Have to Offer?;South Asian Journal of Cancer;2024-07-10

4. Anaplastic Large-cell Lymphoma in Children: State of the Art in 2023;Journal of Pediatric Hematology/Oncology;2024-06-24

5. Measurable residual disease (MRD)-testing in haematological and solid cancers;Leukemia;2024-04-18